STAFF BOARD
Article
CHAIRMAN
Virginia Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Ramón Jódar Masanés
Lluís Campins Bernadas
Tomás Casasín Edo
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 21 - Issue 5, September-October 2019
EDITORIAL
A CASE REPORT OF LEDIPASVIRSOFOSBUVIR OFF-LABEL USE IN A 10 YEARS OLD PEDIATRIC PATIENT
GÓMEZ DE RUEDA FÉLIX, CANCELA DÍEZ BÁRBARA, TENA SEMPERE MARÍA EUGENIA, PÉREZ PARRAS AURORA, ARÉVALO GARRIDO ANA


Ledipasvir-Sofosbuvir (LDV/SOF) is a novel fixed-dose combination of Direct-acting antiviral Agents (DAA), marketed for the treatment of hepatitis C virus, genotypes 1, 4, 5 or 6. It is an association of powerful inhibitors of NS5A protein and NS5B polymerase, essential for RNA replication. The aim of this case report is to share a sentinel experience of a hepatitis C genotype 1 in a 10-year-old infant case, who after evaluating his evolution and the current availability of novel direct-acting antivirals, decided to treat with ledipasvir-sofosbuvir with adult doses. Despite being a child, his weight, height and BMI (body mass index), were definitive to treat him with adult doses as an off-label treatment. This decision was taken into consideration by the pediatricians after they asked for a query to the Digestive and Hospital Pharmacy Units, which supervised at all times the evolution of the patient and their pharmacotherapeutic results.

CHRONIC HEPATITIS C – LEDIPASVIR-SOFOSBUVIR – PEDIATRIC



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25